Day One Biopharmaceuticals’ IPO

Wilson Sonsini Goodrich & Rosati and Fenwick & West LLP advised Day One Biopharmaceuticals on the deal.

San Francisco-based Day One Biopharmaceuticals, a Phase 2 biotech developing treatments for pediatric glioma and other cancers, filed with the SEC to raise up to $100 million in an initial public offering. Day One plans to list on the Nasdaq under the symbol “DAWN.” No pricing terms were disclosed.

Day One Biopharmaceuticals aims to treat patients of all ages with genetically defined cancers, but is initially focused on pediatric patients, which it believes have been underserved by recent cancer treatment advancements. The company’s lead candidate, DAY101, is an oral, brain-penetrant, highly-selective type II pan-rapidly accelerated fibrosarcoma, or pan-RAF, kinase inhibitor. The company has initiated a pivotal Phase 2 trial for DAY101 for the treatment of pediatric patients with relapsed or progressive low-grade glioma, for which DAY101 has been granted Breakthrough Therapy designation. The company anticipates an initial data readout in the 1H22, and expects to file an NDA in 2023.

The offering closed on On June 1, 2021.

The Wilson Sonsini team representing Day One in IP matters related to the transaction includes Maya Skubatch (Picture), Julia Minitti, and Ying Chen.

The Fenwick transaction team included corporate partners Effie Toshav, Robert Freedman, Julia Forbess and Ryan Slunaker and associates Eugene Karlik, Darius Alam, Myles Gutenkunst, Adam Conway, Tim Wilson and Alexej Ladonnikov; executive compensation and employee benefits partner Marshall Mort and associates Jonathan Stephenson and Christophe Delrieu.

Involved fees earner: Adam Conway – Fenwick & West LLP; Christophe Delrieu – Fenwick & West LLP; Julia Forbess – Fenwick & West LLP; Robert Freedman – Fenwick & West LLP; Myles Gutenkunst – Fenwick & West LLP; Eugene Karlik – Fenwick & West LLP; Alexej Ladonnikov – Fenwick & West LLP; Marshall Mort – Fenwick & West LLP; Ryan Slunaker – Fenwick & West LLP; Jonathan Stephenson – Fenwick & West LLP; Effie Toshav – Fenwick & West LLP; Ying Chen – Wilson Sonsini Goodrich & Rosati; Julia Minitti – Wilson Sonsini Goodrich & Rosati; Maya Skubatch – Wilson Sonsini Goodrich & Rosati;

Law Firms: Fenwick & West LLP; Wilson Sonsini Goodrich & Rosati;

Clients: Day One Biopharmaceuticals;

Author: Martina Bellini